Prostate cancer (PCa) is the second leading cause of cancer death among men in the United States and Europe [1]. In China, the rate of PCa increased dramatically [2], and most newly diagnosed patients present metastatic prostate cancer (mPCA). The overall 5-year survival rate of PCa and mPCA is 98.2 and 30.0%, respectively [3].
Androgen deprivation therapy (ADT) is a standard treatment for newly diagnosed mPCa patients. This treatment is effective in up to 95% of patients; however, cancer progresses to metastatic castration-resistant prostate cancer (mCRPC) in most cases [4]. A randomized controlled trial [5] showed that the median failure-free survival (FFS) in mPCa patients treated with ADT was 11 months. Although drug therapies have improved significantly in recent years, mCRPC is still an intractable problem for oncologists. Furthermore, more than one-third of patients without primary lesion treatment developed ureteric obstruction, bladder outlet obstruction (BOO), and other complications because of the primary lesion progression of PCa [6].

Data from the Surveillance Epidemiology and End Result (SEER) database [7] from 2014 showed that the 5-year overall survival (OS) and cancer-specific survival (CSS) were significantly higher in mPCa patients receiving definitive treatment for PCa (cytoreductive radical prostatectomy [CRP] or brachytherapy) compared with untreated patients. Heidenreich et al. [8] showed that ADT plus CRP was feasible for patients with longer life expectancy and reduced the risk of locally recurrent PCa and local complications. The STAMPEDE study [9] indicated that ADT plus prostate radiotherapy improved FFS in mPCa patients and prolonged OS in low metastatic burden patients. The HORRAD study [10] showed that ADT combined with external beam radiation therapy improved prostate-specific antigen (PSA) recurrence-free survival in patients with primary bone mPCa.

Cryoablation (CA) is a minimally invasive and feasible local treatment for PCa. The best practice statement on prostate cryosurgery 2008 [11] reported the safety, reliability, and indications of CA for treating localized PCa. However, few studies have evaluated the outcomes of mPCa after primary lesion CA.

The purpose of this study is to evaluate the oncological results and clinical value of prostate CA plus ADT compared with ADT alone for newly diagnosed mPCa.

**Patients and methods**

**Patient selection**

Data were collected from an institutional review board-approved PCa database from the Sun Yat-Sen University Cancer Center. This retrospective study complied with the Declaration of Helsinki and was approved by the Ethics Committee of Sun Yat-Sen University Cancer Center. Patients gave informed written consent before they chose cryoablation and ADT as their therapy. Patients received digital rectal examination, assessment of clinical symptoms, and serum PSA level. Then, radiological examinations including isotope bone scan, computed tomography (CT) and/or magnetic resonance imaging (MRI) were performed to assess the tumor condition of the prostate and other parts of the body. Prostate biopsy and pathological analysis were then carried out. The inclusion criteria were patients who were newly diagnosed mPCa and received ADT plus whole-gland prostate CA or ADT alone as the first-line therapy. The patients who received chemotherapy, abiraterone acetate plus prednisone, radiotherapy, or prostatectomy at the mHSPC stage were excluded. Fifty-four consecutive patients underwent ADT plus whole-gland prostate CA (group A), and 112 cases received ADT alone at the metastatic hormone-sensitive prostate cancer (mHSPC) stage from January 2011 to November 2018.

**Study variables**

Patient baseline data on age, urinary symptoms, ECOG performance status (ECOG PS), PSA levels, Gleason score, clinical stage, and metastatic burden were collected. Post-treatment data, including urinary symptoms, PSA levels, imaging information, complications, therapies after mCRPC, and patient survival, were recorded. mCRPC was defined according to the European Association of Urology Guideline [12] as castrate serum testosterone <50 ng/dL (1.7 nmol/L) combined with one of these events: biochemical progression (three consecutive increases in PSA at least 1 week apart resulting in two 50% increases above nadir, and PSA > 2 ng/mL), and radiological progression (appearance of new lesions, including at least two new bone lesions on bone scan or a soft tissue lesion using Response Evaluation Criteria in Solid Tumors). The metastatic burden was classified as high or low according to the criteria established in the STAMPEDE trial [9]. High metastatic burden was defined as at least four bone metastases with at least one outside pelvis or the vertebral bodies; or visceral metastases; or both. Others were seen as patients with low metastatic burden. The primary endpoint was FFS, which was defined [13] as the interval from diagnosis of PCa to one of the following: PSA > 4 ng/mL and at least 50% increase over the lowest level; progression of lymph nodes, local disease, or distant metastases; or death due to PCa. CSS was defined as the period from diagnosis of PCa to death from PCa. OS was defined as the period from the initial diagnosis of PCa to death from any cause. Urinary symptom relief at the mHSPC stage and complications due to primary lesions at the mCRPC stage were assessed by patient complaints and medical history. Urinary symptoms were defined as lower urinary tract symptoms and hematuria. Local complications due to primary lesions were defined as BOO, hematuria, acute urinary retention, and ureteric obstruction, as detailed previously [6].

**CA and ADT**

Whole-gland prostate CA was conducted under transrectal ultrasonography guidance. The process involves two
freeze-thaw cycles [14]. Each patient received prostate cryosurgery at the mHSPC stage. ADT included the continuous infusion of a luteinizing hormone-releasing hormone agonist or bilateral orchiectomy, and serum testosterone was measured to guarantee that the enrolled patients presented the minimum accepted level (<50 ng/dL).

**Follow-up**

After treatment, all patients were followed-up every 1–3 months. Digital rectal examination and assessment of clinical symptoms and serum PSA levels were performed at 1- to 3-month intervals. Radiological examinations, including isotope bone scan, CT, or MRI, were performed every 6–12 months. In patients with PSA progression or clinical symptoms, radiological examination was carried out to assess disease activity and formulate a treatment plan.

**Statistical analysis**

To compare prostate CA plus ADT vs. ADT alone, baseline clinical characteristics, including age, ECOG PS, PSA levels, Gleason score, clinical stage, and metastatic burden, were balanced using propensity score matching (PSM) at a ratio of 1:1. Log-rank calculation formula of sample size was applied to calculate sample power. In the descriptive analysis, normally distributed quantitative data were shown as means and standard deviations, and non-normally distributed data were expressed as median and interquartile range. Qualitative data were represented as frequencies and percentages. A two-sample t-test was used to compare the means of continuous variables with normal distribution, and the Wilcoxon rank sum test was used to compare non-normally distributed continuous variables. A Chi-square test was used for categorical data. The Kaplan–Meier method was used for survival analysis, and the log-rank test was used for statistical significance testing. Univariate and multivariate Cox proportional hazards analyses were performed to assess the prognostic value of additional CA. A two-sided p value of less than 0.05 was considered to indicate a statistically significant difference. PSM and statistical analyses were performed using SPSS software version 25.0.

**Results**

**Patient characteristics**

A total of 108 patients were evaluated after PSM (54 in group A [CA plus ADT] and 54 in group B [ADT only]). The baseline characteristics of the study population are shown in Table 1. Seven (13.0%) patients in group A had lung metastases. Eight (14.8%) patients in group B had at least four bone metastases with at least one outside pelvis or the vertebral bodies; or visceral metastases; or both.

| Variable                          | Total cohort | Group A | Group B | p value |
|----------------------------------|-------------|---------|---------|---------|
| Patients (n)                     | 108         | 54      | 54      |         |
| Age (years)                      | 67.8 ± 8.7  | 68.2 ± 8.3 | 67.5 ± 9.2 | 0.685 |
| ECOG PS                          |             |         |         | 0.428  |
| 0                                | 91 (84.3%)  | 44 (81.5%) | 47 (87.0%) |       |
| >0                               | 17 (15.7%)  | 10 (18.5%) | 7 (13.0%)  |       |
| PSA (ng/mL)                      | 78.8 (32.9–156.2) | 63.1 (31.5–116.8) | 97.2 (35.6–217.6) | 0.144 |
| Gleason score ≥8                 | 65 (60.2%)  | 30 (55.6%) | 35 (64.8%) | 0.326  |
| Gleason score <8                 | 43 (39.8%)  | 24 (44.4%) | 19 (35.2%) |       |
| T Stage ≥3                       | 65 (60.2%)  | 31 (57.4%) | 34 (63.0%) | 0.555  |
| T Stage <3                       | 43 (39.8%)  | 23 (42.6%) | 20 (37.0%) |       |
| N Stage 0                        | 50 (46.3%)  | 29 (53.7%) | 21 (38.9%) | 0.123  |
| N Stage 1                        | 58 (53.7%)  | 25 (46.3%) | 33 (61.1%) |       |
| Visceral metastases 0            | 93 (86.1%)  | 47 (87.0%) | 46 (85.2%) | 0.781  |
| Visceral metastases 1            | 15 (13.9%)  | 7 (13.0%) | 8 (14.8%) |       |
| Metastatic burden Low            | 49 (45.4%)  | 25 (46.3%) | 24 (44.4%) | 0.847  |
| Metastatic burden High*          | 59 (54.6%)  | 29 (53.7%) | 30 (55.6%) |       |
| Prostate volume (mL³)            | 30.6 (19.5–43.4) | 31.3 (20.7–36.8) | 30.4 (18.9–49.0) | 0.351  |

Group A, cryoablation combined with androgen deprivation therapy (ADT); group B, ADT alone.
ECOG PS Eastern Cooperative Oncology Group Performance Status, PSA prostate-specific antigen.

*a*at least four bone metastases with at least one outside pelvis or the vertebral bodies; or visceral metastases; or both.
metastasis to different organs, including lungs (N = 5), meninges (N = 1), lung and thyroid (N = 1), and lung and liver (N = 1).

**Oncological outcomes**

The median follow-up time was 40 (27–53) months in group A and 39 (31–54) months in group B (p = 0.263). The median serum PSA nadir in group A was lower than that in group B (0.025 ng/mL vs. 0.230 ng/mL, p = 0.001). Until the last follow-up, 25 (46.3%) patients in group A and 42 (77.8%) patients in group B progressed to mCRPC. mCRPC patients in group A received abiraterone acetate plus prednisone (11, 44.0%), chemotherapy (3, 12.0%), estramustine phosphate (6, 24.0%), or flutamide (3, 12.0%). mCRPC patients from group B received abiraterone acetate plus prednisone (18, 42.9%), chemotherapy (14, 33.3%), estramustine phosphate (13, 40.0%), or flutamide (3, 7.1%). The patients in group A had longer FFS and mCRPC-free survival than group B (39 months vs. 21 months, p = 0.005; 39 months vs. 21 months, p = 0.007, respectively) (Table 2). The Kaplan–Meier curve showed that patients in group A had longer FFS and mCRPC-free survival (logrank test p = 0.005, p = 0.007, Figs. 1 and 2). The univariate analysis showed that FFS was significantly associated with T stage, metastatic burden, and additional CA (p = 0.006, p = 0.046, p = 0.007, respectively). After adjusting for the effects of these parameters in the multivariate analysis, CA was an independent predictor of FFS (hazard ratio, 0.542; 95% confidence interval, 0.329–0.893; p = 0.016) (Table 3).

There was no significant difference in CSS and OS between the two groups (Figs. 3 and 4).

Among patients with low metastatic burden, PSA nadir was lower in group A than in group B (0.030 ng/mL vs. 0.173 ng/mL, p = 0.037). Among patients with high metastatic burden, group A had lower median PSA nadir, longer median FFS and median time to mCRPC, and decreased mortality from PCa than group B (p = 0.012, p = 0.010, p = 0.011, and p = 0.044, respectively) (Table 2).

**Symptom control and primary lesion treatment**

CA was well tolerated in 54 mPCa patients within 6 months of ADT. No patients died during surgery, and no patients presented urethrocervical fistula or urinary incontinence. The complications were shown in Table 4 according to Clavien–Dindo Classification. Nonetheless, these complications disappeared within 4 weeks after surgery. Forty-three patients (79.6%) in group A and 44 patients (81.5%) in group B had urinary symptoms at diagnosis, respectively. Patients in group A had greater relief of urinary symptoms at the mHSPC stage (79.1 vs. 59.1%, p = 0.044, Table 5). At the mCRPC stage,

![Image](https://via.placeholder.com/150)

**Table 2 Oncological results in the study cohort according to the degree of metastasis.**

| Outcome                          | Group A | Group B | p value |
|----------------------------------|---------|---------|---------|
| Median follow-up (mo)            | 40 (27–53) | 39 (31–54) | 0.263   |
| All patients                     | 54      | 54      |         |
| Median PSA nadir, ng/mL          | 0.025 (0.003–0.273) | 0.230 (0.051–1.035) | 0.001   |
| Median FFS (mo)                  | 39.0 ± 5.79 | 21.0 ± 5.13 | 0.005   |
| Median time to mCRPC (mo)        | 39.0 ± 7.22 | 21.0 ± 5.71 | 0.007   |
| Median CSS (mo)                  | NR      | 75.0 ± 6.50 | 0.849   |
| Median OS (mo)                   | NR      | 67.0 ± 12.18 | 0.851   |
| Deaths from all causes           | 20 (37.0%) | 23 (42.6%) | 0.555   |
| Low metastatic burden patients   | 25      | 24      |         |
| Median PSA nadir, ng/mL          | 0.030 (0.003–0.222) | 0.173 (0.041–1.001) | 0.037   |
| Median FFS (mo)                  | NR      | 28.0 ± 15.90 | 0.190   |
| Time to mCRPC (mo)               | NR      | 26.0 ± 14.98 | 0.195   |
| Median CSS (mo)                  | 60.0 ± 10.00 | NR       | 0.280   |
| Median OS (mo)                   | 54.0 ± 5.72 | NR       | 0.144   |
| Deaths from PCa                  | 7 (28.0%) | 4 (16.7%) | 0.342   |
| Deaths from all causes           | 10 (40.0%) | 5 (20.8%) | 0.146   |
| High metastatic burden patients  | 29      | 30      |         |
| Median PSA nadir, ng/mL          | 0.020 (0.003–0.459) | 0.258 (0.079–1.035) | 0.012   |
| Median FFS (mo)                  | 46.0 ± 10.24 | 18.0 ± 6.16 | 0.010   |
| Time to mCRPC (mo)               | 44.0 ± 8.53 | 15.0 ± 6.16 | 0.011   |
| Median CSS (mo)                  | NR      | 66.0 ± 9.78 | 0.434   |
| Median OS (mo)                   | NR      | 52.0 ± 14.98 | 0.488   |
| Deaths from PCa                  | 8 (27.6%) | 16 (53.3%) | 0.044   |
| Deaths from all causes           | 10 (34.5%) | 18 (60.0%) | 0.050   |

Group A, cryoablation + ADT. Group B, ADT alone. ADT androgen deprivation therapy, mo months, PSA prostate-specific antigen, FFS failure-free survival, mCRPC metastatic castration-resistant prostate cancer, CSS cancer-specific survival, OS overall survival, PCa prostate cancer, NR not reached.
complications due to primary lesion progression occurred in eight (32.0%) patients in group A and 18 (42.9%) patients in group B ($p = 0.378$, Table 5 Supplementary Table 1). Seven (13.0%) patients in group A and 17 (31.5%) in the control group received local treatment of primary lesions for symptomatic relief ($p = 0.021$). The chosen treatments were transurethral resection of the prostate (TURP) (one patient, 1.9%), urethral dilation (five patients, 9.3%), or radiotherapy (one patient, 1.9%) in group A, and TURP (two patients, 3.7%), suprapubic cystostomy (one patient, 1.9%), catheterization (two patients, 3.7%), or radiotherapy (12 patients, 22.2%) in group B.

**Discussion**

In this retrospective study, PSM was applied to determine the oncological and clinical efficacy of additional CA with ADT for treating newly diagnosed mPCa. The results showed that combination therapy reduced serum PSA nadir, prolonged FFS and mCRPC-free survival, relieved urinary symptoms at the mHSPC stage, and reduced the need for the palliative treatment of primary tumors.

Although ADT is one of standard therapies for mPCa, recent studies have shown that mPCa patients may benefit from the local treatment of PCa. Two randomized trials [9, 10] showed that additional radiotherapy increased survival in low metastatic burden patients. Leyh-Bannurah et al. [15] used SEER data to demonstrate that radical prostatectomy improved CSS, especially in M1a patients.

![Fig. 2 Metastatic castration-resistant prostate cancer-free survival in the study population. Group A cryoablation + ADT, group B ADT alone, ADT androgen deprivation therapy. mCRPC metastatic castration-resistant prostate cancer.](image)

**Table 3** Cox proportional hazards analysis of failure-free survival in the study population.

| Variables | Univariate analysis | Multivariate analysis |
|-----------|---------------------|----------------------|
|           | HR (95% CI)         | p value              | HR (95% CI)         | p value              |
| Age (years) | 0.984 (0.956–1.012) | 0.255               | –                   | –                   |
| ECOG PS 0 | 1                   | 0.603               | –                   | –                   |
| >0        | 1.188 (0.621–2.269) | 0.701               | 0.616               | 0.719               |
| PSA (ng/mL) | 1.001 (1.000–1.001) | 0.054               | 1 (1.000–1.001)     | 0.443               |
| Gleason score | 0.068               | 0.193               | 0.193               | 0.193               |
| <8        | 1                   | 1                   | 1                   | 1                   |
| ≥8        | 1.597 (0.965–2.642) | 0.006               | 1.411 (0.840–2.369) | 0.026               |
| T Stage <3 | 1                   | 0.028               | 0.026               | 0.859               |
| ≥3        | 2.127 (1.243–3.637) | 1.881 (1.078–3.283) | 1.881 (1.078–3.283) | 1.881 (1.078–3.283) |
| N Stage 0 | 1                   | 0.945               | 0.463               | 0.463               |
| 1         | 1.300 (0.801–2.112) | 1.048 (0.626–1.753) | 0.626 (0.359–1.594) | 1.048 (0.626–1.753) |
| Visceral metastases 0 | 1                   | 0.945               | 0.463               | 0.463               |
| 1         | 1.025 (0.507–2.027) | 0.757 (0.359–1.594) | 0.359 (0.159–0.814) | 0.162               |
| Metastatic burden Low | 1                   | 0.046               | 0.046               | 0.046               |
| High      | 1.657 (1.009–2.722) | 1.712 (1.010–2.903) | 1.010–2.903         | 1.010–2.903         |
| Cryoablation | 0.505 (0.308–0.830) | 0.007               | 0.542 (0.329–0.893) | 0.016               |

**ECOG PS** Eastern Cooperative Oncology Group Performance Status, **PSA** prostate-specific antigen, **HR** hazard ratio, **CI** confidence interval.
Heidenreich et al. [8] performed a case-control study and showed that CRP plus ADT prolonged PFS and OS in low metastatic burden patients; however, only 23 patients were included in the operation group, and their PSA levels were lower than those in the control group before treatment ($p = 0.049$).

Few studies have evaluated the clinical efficacy and oncological outcomes of CA in mPCa, although this treatment is minimally invasive and effective. Si et al. [16] found that CA plus ADT prolonged PFS, CSS, and OS in mPCa patients ($p < 0.01$). However, only 30 patients were included in the CA group, and the patients in the ADT group were selected by pair-matched analysis, which might have caused selection bias. Our analysis used PSM to avoid this type of bias, and the results showed that CA plus ADT prolonged FFS and mCRPC-free survival, and achieved lower median PSA nadir in mPCa patients. Some studies [17–19] have shown that the PSA nadir is a powerful predictor of OS in mPCa patients receiving ADT.

Additional CA in mPCa patients might achieve antitumor effects by delaying cancer metastasis and improving immunity. Chu et al. [20] demonstrated that intact tumor-specific antigens produced by tumor CA in situ could trigger an immune response and help fight cancer. Benzon et al. [21] analyzed the curative effect of CA and immune therapy in a mouse model and found that combination treatment postponed the growth of metastatic tumors ($p = 0.0006$). Connor et al. [22] found that minimally invasive ablative therapies, including CA, killed tumor cells and induced cellular and humoral antitumor immune responses by releasing tumor-associated antigens. Our results showed that CA plus ADT prolonged FFS and mCRPC-free survival, and reduced mortality in high metastatic burden patients receiving CA (Table 2). We hypothesized that systemic antitumor immunity activated by CA played a role, although Kaplan–Meier and log-rank analyses showed that there were no significant intergroup differences in CSS. The small sample size may have caused bias, and larger studies are necessary to evaluate patients with high metastatic burden. These outcomes support that killing cells from the primary tumor may prevent metastasis.

ADT may not completely relieve urinary symptoms in mPCa patients, and primary lesion progression may cause complications. Choi et al. [23] analyzed International Prostate Symptom Score (IPSS) voiding symptoms in 110 PCa patients treated with ADT and found that ADT improved the IPSS, but the curative effect decreased after 1 year of treatment ($-4.10$ within 1 year vs. $-2.65$, $p < 0.05$). Akpayak et al. [24] carried out a prospective study and showed that 12 months after ADT, the IPSS decreased in 50.8% of mPCa patients with moderate or severe urinary symptoms. Furthermore, urinary symptoms may have worsened in patients in which PCa progressed to mCRPC. Won et al. [6] showed that 54.3% of patients who underwent ADT alone had complaints at the CRPC stage, and

![Fig. 3 Cancer-specific survival in the study population. Group A cryoablation + ADT, group B ADT alone, ADT androgen deprivation therapy, CSS cancer-specific survival.](image)

![Fig. 4 Overall survival in the study population. Group A cryoablation + ADT, group B ADT alone, ADT androgen deprivation therapy, OS overall survival.](image)

### Table 4 Cryoablation-related complications stratified by Clavien–Dindo classification.

| Complications       | No. of patients |
|---------------------|-----------------|
| Grade I             | 13 (24.1%)      |
| Scrotal edema       | 8 (14.8%)       |
| Hematuria           | 3 (5.6%)        |
| Urinary retention   | 2 (3.7%)        |
| Grade II            | 0               |
| Grade III           | 0               |
| Grade IV            | 0               |

lower median PSA nadir in mPCa patients. Some studies [17–19] have shown that the PSA nadir is a powerful predictor of OS in mPCa patients receiving ADT.

ADT may not completely relieve urinary symptoms in mPCa patients, and primary lesion progression may cause complications. Choi et al. [23] analyzed International Prostate Symptom Score (IPSS) voiding symptoms in 110 PCa patients treated with ADT and found that ADT improved the IPSS, but the curative effect decreased after 1 year of treatment ($-4.10$ within 1 year vs. $-2.65$, $p < 0.05$). Akpayak et al. [24] carried out a prospective study and showed that 12 months after ADT, the IPSS decreased in 50.8% of mPCa patients with moderate or severe urinary symptoms. Furthermore, urinary symptoms may have worsened in patients in which PCa progressed to mCRPC. Won et al. [6] showed that 54.3% of patients who underwent ADT alone had complaints at the CRPC stage, and

![Fig. 3 Cancer-specific survival in the study population. Group A cryoablation + ADT, group B ADT alone, ADT androgen deprivation therapy, CSS cancer-specific survival.](image)

![Fig. 4 Overall survival in the study population. Group A cryoablation + ADT, group B ADT alone, ADT androgen deprivation therapy, OS overall survival.](image)

### Table 4 Cryoablation-related complications stratified by Clavien–Dindo classification.

| Complications       | No. of patients |
|---------------------|-----------------|
| Grade I             | 13 (24.1%)      |
| Scrotal edema       | 8 (14.8%)       |
| Hematuria           | 3 (5.6%)        |
| Urinary retention   | 2 (3.7%)        |
| Grade II            | 0               |
| Grade III           | 0               |
| Grade IV            | 0               |

lower median PSA nadir in mPCa patients. Some studies [17–19] have shown that the PSA nadir is a powerful predictor of OS in mPCa patients receiving ADT.

ADT may not completely relieve urinary symptoms in mPCa patients, and primary lesion progression may cause complications. Choi et al. [23] analyzed International Prostate Symptom Score (IPSS) voiding symptoms in 110 PCa patients treated with ADT and found that ADT improved the IPSS, but the curative effect decreased after 1 year of treatment ($-4.10$ within 1 year vs. $-2.65$, $p < 0.05$). Akpayak et al. [24] carried out a prospective study and showed that 12 months after ADT, the IPSS decreased in 50.8% of mPCa patients with moderate or severe urinary symptoms. Furthermore, urinary symptoms may have worsened in patients in which PCa progressed to mCRPC. Won et al. [6] showed that 54.3% of patients who underwent ADT alone had complaints at the CRPC stage, and
symptoms than the control group (Table 5). Moreover, patients in the CA group had higher relief of urinary complications in mPCa patients. In the present study, CRP combined with ADT reduced the risk of local complications compared to the control group without CRP (7.0 vs 35%; \( p < 0.01 \)). Heidenreich et al. [8] found that CRP combined with ADT reduced the risk of local complications in mPCa patients. In the present study, patients in the CA group had higher relief of urinary symptoms than the control group (Table 5). Moreover, fewer mPCa patients in the CA group had complications at the mCRPC stage, although the intergroup difference was not significant (32.0 vs. 42.9%, \( p = 0.378 \)). The most common complication after mCRPC in our cohort was BOO, which is in accordance with the results of Won et al. [6]. In addition, the CA group required less palliative treatment of primary lesions for symptomatic relief compared to the control group (13.0 vs. 31.5%, \( p = 0.021 \)). Compared with CRP, CA was less invasive for mPCa patients, who were predominantly elderly people; nonetheless, the oncological outcomes of localized PCa were similar between CA and radical prostatectomy [26, 27].

This study has some limitations. First, the retrospective nature of the study may have led to bias. Second, the follow-up period was not long enough to achieve median CSS and OS in the CA group. Third, the number of cases was small. Notwithstanding, a prospective randomized control clinical trial is in progress in our hospital to address these limitations.

### Conclusions

Our results suggest that prostate CA combined with ADT for newly diagnosed mPCa patients improves oncologic outcomes with longer FFS and mCRPC-free survival, and lower PSA nadir. Moreover, this combination treatment can reduce urinary symptoms and decrease the need for treating primary lesions for symptomatic relief. Notwithstanding, further prospective studies are needed to confirm these conclusions.

### Acknowledgements

This study was supported by the National Natural Science Foundation of China (Process Nos. 81772726 and 81802553), and Clinical Research 308 Program of Sun Yat-sen University Cancer Center.

### Compliance with ethical standards

**Conflict of interest** The authors declare no competing interests.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### References

1. Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018;25:524–31.
2. Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.
3. Damodaran S, Lang JM, Jarrard DF. Targeting metastatic hormone-sensitive prostate cancer: chemohormonal therapy and new combinatorial approaches. J Urol. 2019;201:876–85.
4. Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Firazzi K, Kheoh T, et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer. 2017;84:88–101.
5. James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67:1028–38.
6. Won AC, Gurney H, Marx G, De Souza P, Patel MI. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int. 2013;112:E250–5. https://doi.org/10.1111/bju.12169.
7. Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment...
of the primary tumor? A SEER-based study. Eur Urol. 2014; 65:1058–66.
8. Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193:832–8.
9. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353–66.
10. Boeve LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75:410–8.
11. Babaian RJ, Donnelly B, Bahn D, Baust JG, Dineen M, Ellis D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2008;180:1993–2004.
12. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2020;S0302-2838(20)30773-9. https://doi.org/10.1016/j.eururo.2020.09.046.
13. Sydes MR, Spears MR, Mason MD, Clarke NW, Dearnaley DP, de Bono JS, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29:1235–48.
14. de Castro Abreu AL, Bahn D, Leslie S, Shoji S, Silverman P, Desai MM, et al. Salvage focal and salvage total cryoablation for locally recurrent prostate cancer after primary radiation therapy. BJU Int. 2013;112:298–307.
15. Leyh-Bannurah SR, Gazdovich S, Budaus L, Zaffuto E, Briganti A, Abdollah F, et al. Local therapy improves survival in metastatic prostate cancer. Eur Urol. 2017;72:118–24.
16. Si T, Guo Z, Yang X, Zhang W, Xing W. The onologic results of cryoablation in prostate cancer patients with bone metastases. Int J Hyperth. 2018;34:1044–8.
17. Tomioka A, Tanaka N, Yoshikawa M, Miyake M, Anai S, Chihara Y, et al. Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer. BMC Urol. 2014;14:33.
18. Hong SY, Cho DS, Sun IK, Ahn HS, Kim SJ. Prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer. Korean J Urol. 2012;53:607–13.
19. Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009;27:2450–6.
20. Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14:199–208.
21. Benzon B, Glavaris SA, Simons BW, Hughes RM, Ghabili K, Mullane P, et al. Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer. Prostate Cancer Prostatic Dis. 2018;21:126–36.
22. Connor MJ, Shah TT, Horan G, Bevan CL, Winkler M, Ahmed HU. Cytoreductive treatment strategies for de novo metastatic prostate cancer. Nat Rev Clin Oncol. 2020;17:168–82.
23. Choi H, Chung H, Park JY, Lee JG, Bae JH. The influence of androgen deprivation therapy on prostate size and voiding symptoms in prostate cancer patients in Korea. Int Neurol J. 2016;20:342–8.
24. Akpayak IC, Shuaibu SI, Ofoha CG, Dakum NK, Ramyil VM, Onowa VE, et al. Lower urinary tract symptoms in patients with advanced prostate cancer: What are the outcomes of androgen deprivation therapy? Niger Postgrad Med J. 2020;27:49–53.
25. Steuber T, Berg KD, Roder MA, Brasso K, Iversen P, Huland H, et al. Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? results from a prospective case-control study. Eur Urol Focus. 2017;3:646–9.
26. Langenhuijsen JF, Broers EM, Vergunst H. Cryosurgery for prostate cancer: an update on clinical results of modern cryotechnology. Eur Urol. 2009;55:76–86.
27. Cohen JK, Miller RJ Jr, Ahmed S, Lotz MJ, Baust J. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology. 2008;71:515–8.